Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Reilly Website

Karlyne M. Reilly, Ph.D.

Selected Publications
1)  Reilly KM, Van Dyke T.
It takes a (dysfunctional) village to raise a tumor.
Cell. 135: 408-10, 2008. [Journal]
2)  Hawes JJ, Nerva JD, Reilly KM.
Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening. 13: 795-803, 2008. [Journal]
3)  Tuskan RG, Tsang S, Sun Z, Baer J, Rozenblum E, Wu X, Munroe DJ, Reilly KM.
Real-time PCR analysis of candidate imprinted genes on mouse chromosome 11 shows balanced expression from the maternal and paternal chromosomes and strain-specific variation in expression levels.
Epigenetics : official journal of the DNA Methylation Society. 3: 43-50, 2008. [Journal]
4)  Reilly KM, Rubin JB, Gilbertson RJ, Garbow JR, Roussel MF, Gutmann DH.
Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop.
Cancer Res. 68: 5508-11, 2008. [Journal]
5)  Hawes JJ, Tuskan RG, Reilly KM.
Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.
Neurogenetics. 8: 121-30, 2007. [Journal]
6)  Reilly KM, Broman KW, Bronson RT, Tsang S, Loisel DA, Christy ES, Sun Z, Diehl J, Munroe DJ, Tuskan RG.
An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model.
Cancer Res. 66: 62-8, 2006. [Journal]
7)  Gursel D, Reilly K.
Models of Astrocytoma.
Drug Discovery Today: Disease Models. 2: 77-83, 2005. Full Text Article. [Journal]
8)  Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, Messerli SM, McClatchey AI, Niwa-Kawakita M, Ratner N, Reilly KM, Zhu Y, Giovannini M.
Comparative pathology of nerve sheath tumors in mouse models and humans.
Cancer Res. 64: 3718-24, 2004. [Journal]
9)  Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT, Smith CD, Tsang S, Munroe DJ, Jacks T.
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.
Proc Natl Acad Sci U S A. 101: 13008-13, 2004. [Journal]
10)  Reilly KM.
The Importance of Genome Architecture in Cancer Susceptibility: Location, Location, Location.
Cell Cycle. 3, 2004. [Journal]
11)  Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H.
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.
J Transl Med. 2: 40, 2004. [Journal]
12)  Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, Marino S, Radovanovic I, Reilly K, Aldape K.
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum.
Oncogene. 21: 7453-63, 2002. [Journal]
13)  Reilly KM, Jacks T.
Genetically engineered mouse models of astrocytoma: GEMs in the rough.
Semin Cancer Biol. 11: 177-191, 2001. [Journal]
14)  Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH.
Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes.
Glia. 33: 314-323, 2001. [Journal]
15)  Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T.
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.
Nat Genet. 26: 109-113, 2000. [Journal]
16)  Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T.
Mouse models of tumor development in neurofibromatosis type 1.
Science. 286: 2172-2176, 1999. [Journal]

This page was last updated on 12/12/2008.